<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01873274</url>
  </required_header>
  <id_info>
    <org_study_id>12-3-009</org_study_id>
    <nct_id>NCT01873274</nct_id>
  </id_info>
  <brief_title>Comparative Study Menaquinone-7</brief_title>
  <official_title>Comparative Study of Three Delivery Systems of Menaquinone-7</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the absorption of menaquinone-7 from a&#xD;
      nutrient-enriched dairy product compared to a general dairy product enriched with&#xD;
      menaquinone-7 and a menaquinone-7-containing supplement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an earlier study, beneficial effects of a nutrient-enriched dairy product on vitamin&#xD;
      K-status were observed. The study product contained menaquinone-7 (MK-7) and omega-3 fatty&#xD;
      acids for vascular health and extra minerals and antioxidants to support general health. It&#xD;
      was the first time that such low dose of MK-7 (50 µg) could significantly improve vascular&#xD;
      and general vitamin K-status already after short-term treatment. From the results of this&#xD;
      study, it was assumed that the matrix of the dairy product and/or other components in the&#xD;
      product, in which the vitamin was offered, contributed to optimal absorption and availability&#xD;
      of vitamin K2. In this new study, the uptake and efficacy of MK-7 from the nutrient enriched&#xD;
      product is investigated and compared to the uptake and efficacy from a MK-7-containing&#xD;
      supplement and a basic dairy product enriched with MK-7.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in plasma MK-7 concentration after intervention between the three study groups</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in circulating markers of vitamin K-status, undercarboxylated osteocalcin and desphospho-uncarboxylated matrix Gla-protein, after intervention between the three study groups.</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in circulating vitamin D (25-hydroxy-vitamin D) after intervention between the study groups.</measure>
    <time_frame>baseline and 6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Bioavailability</condition>
  <arm_group>
    <arm_group_label>basic yogurt enriched with MK-7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one study group will receive daily two basic dairy products enriched with MK-7 (50 μg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-7 containing capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one study group will receive daily a softgel capsule consisting of 50 μg MK-7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nutrient enriched yogurt with MK-7</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one study group will receive daily two nutrient-enriched dairy products containing extra nutrients and omega-3 FA (fish-oil)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MK-7 containing capsule</intervention_name>
    <arm_group_label>MK-7 containing capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>basic yogurt enriched with MK-7</intervention_name>
    <arm_group_label>basic yogurt enriched with MK-7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>nutrient-enriched yogurt with MK-7</intervention_name>
    <arm_group_label>nutrient enriched yogurt with MK-7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Apparently healthy men and postmenopausal women between 45 and 65 years old&#xD;
&#xD;
          -  Subjects with body weight and height according to BMI between 20 and 30 kg/m2&#xD;
&#xD;
          -  Subjects of Caucasian race&#xD;
&#xD;
          -  Subject has given written consent to take part in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with hypertension&#xD;
&#xD;
          -  Subjects with hypercholesterolemia&#xD;
&#xD;
          -  Subjects with (a history of) metabolic or gastrointestinal disease&#xD;
&#xD;
          -  Subjects presenting chronic degenerative and/or inflammatory disease&#xD;
&#xD;
          -  Subjects with (a history) of diabetes mellitus&#xD;
&#xD;
          -  Abuse of drugs and/or alcohol&#xD;
&#xD;
          -  Subjects receiving corticosteroid treatment&#xD;
&#xD;
          -  Subjects using oral anticoagulants and subjects with clotting disorders&#xD;
&#xD;
          -  Subjects using blood pressure-lowering medication&#xD;
&#xD;
          -  Subjects using cholesterol-lowering medication&#xD;
&#xD;
          -  Subjects using multivitamins or vitamin K supplements&#xD;
&#xD;
          -  Subjects consuming high amounts of vitamin K-containing food products&#xD;
&#xD;
          -  Subjects with cow's milk allergy and lactose intolerance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cees Vermeer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VitaK BV Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VitaK BV / Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>June 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2013</study_first_posted>
  <last_update_submitted>June 12, 2013</last_update_submitted>
  <last_update_submitted_qc>June 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

